ALCNYSEOphthalmic GoodsFiscal year ends December 31
ALCON INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 24, 2026
$66.13−0.05 (-0.08%)
Close on Oct 19, 2026
- Market cap
- $32.32B
- P/E (TTM)
- 33.4
- Dividend yield
- –
ALCON INC revenue by segment
By business segment
| Revenue | Q2 26 | Q2 25 | Q2 24 | Q2 23 | Q2 22 | Q2 21 | Q2 20 | Q2 19 | Q2 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical | $1.57B | $1.46B | $1.42B | – | – | – | – | – | – | 55.6% | +7.9% |
| Vision Care | $1.21B | $1.12B | $1.06B | – | – | – | – | – | – | 42.9% | +8.0% |
| Surgical | – | – | $1.42B | $1.38B | $1.30B | $1.21B | $602.00M | $1.05B | $1.03B | – | – |
| Vision Care | – | – | $1.06B | $1.02B | $904.00M | $888.00M | $612.00M | $852.00M | $789.00M | – | – |
| Operating income | Q2 26 | Q2 25 | Q2 24 | Q2 23 | Q2 22 | Q2 21 | Q2 20 | Q2 19 | Q2 18 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Surgical | $392.00M | $378.00M | $403.00M | – | – | – | – | – | – | +3.7% |
| Vision Care | $283.00M | $208.00M | $180.00M | – | – | – | – | – | – | +36.1% |
By product or service
By region
| Revenue | Q2 26 | Q2 25 | Q2 24 | Q2 23 | Q2 22 | Q2 21 | Q2 20 | Q2 19 | Q2 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| International | $1.54B | $1.42B | $1.34B | $1.30B | $1.21B | $1.14B | $705.00M | – | – | 54.6% | +8.8% |
| United States | $1.24B | $1.16B | $1.14B | $1.11B | $990.00M | $958.00M | $493.00M | – | – | 44.0% | +7.0% |
| Country of domicile | – | – | – | – | – | – | $493.00M | $779.00M | $750.00M | – | – |
| Foreign countries | – | – | – | – | – | – | $705.00M | $1.08B | $1.07B | – | – |
From the segment and revenue-disaggregation notes of Alcon's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.